Discontinued — last reported Q3 '21
Medtronic Stock Issuance Proceeds increased by 2.5% to $164.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 2.4%, from $168.00M to $164.00M. Over 3 years (FY 2022 to FY 2025), Stock Issuance Proceeds shows an upward trend with a 5.8% CAGR.
Higher proceeds typically indicate increased employee participation in equity incentive plans, while lower proceeds may reflect reduced option exercise activity.
Reflects the cash inflows received from the issuance of common stock, primarily driven by employee stock option exercise...
Standard line item for companies with significant equity-based compensation programs for staff and management.
cf_proceeds_from_stock_issuance| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $111.00M | $163.00M | $70.00M | $85.00M | $43.00M | $110.00M | $56.00M | $99.00M | $77.00M | $72.00M | $57.00M | $78.00M | $89.00M | $143.00M | $168.00M | $108.00M | $95.00M | $160.00M | $164.00M |
| QoQ Change | — | +46.8% | -57.1% | +21.4% | -49.4% | +155.8% | -49.1% | +76.8% | -22.2% | -6.5% | -20.8% | +36.8% | +14.1% | +60.7% | +17.5% | -35.7% | -12.0% | +68.4% | +2.5% |
| YoY Change | — | — | — | — | -61.3% | -32.5% | -20.0% | +16.5% | +79.1% | -34.5% | +1.8% | -21.2% | +15.6% | +98.6% | +194.7% | +38.5% | +6.7% | +11.9% | -2.4% |